Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 31

Results For "IMI"

4532 News Found

Establishment Labs seeks FDA nod for Motiva breast reconstruction implants
News | January 01, 2026

Establishment Labs seeks FDA nod for Motiva breast reconstruction implants

Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation


WORK Medical scores regulatory approval for AI-powered blood analyzer
Medical Device | January 01, 2026

WORK Medical scores regulatory approval for AI-powered blood analyzer

It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,


Wockhardt’s WCK 5222 earns accelerated review from European Medicines Agency
News | January 01, 2026

Wockhardt’s WCK 5222 earns accelerated review from European Medicines Agency

The accelerated review covers WCK 5222 for multiple critical infections


Johnson & Johnson completes $3.05 billion acquisition of Halda Therapeutics
News | January 01, 2026

Johnson & Johnson completes $3.05 billion acquisition of Halda Therapeutics

The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease


GenSight Biologics gets early access nod for candidate gene therapy in Israel
Clinical Trials | December 31, 2025

GenSight Biologics gets early access nod for candidate gene therapy in Israel

Applications include detailed scientific rationale and supporting clinical evidence


UK’s healthcare regulator warns against dangerous online weight-loss drugs
Public Health | December 31, 2025

UK’s healthcare regulator warns against dangerous online weight-loss drugs

Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients


CARsgen submits INDs for next-gen CAR-T therapy targeting hard-to-treat blood cancers
Clinical Trials | December 31, 2025

CARsgen submits INDs for next-gen CAR-T therapy targeting hard-to-treat blood cancers

The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively


Cupid to set up FMCG manufacturing facility in Saudi Arabia
News | December 30, 2025

Cupid to set up FMCG manufacturing facility in Saudi Arabia

The plant is expected to enhance regional supply capabilities


Astal signs LoI with Immuna Therapeutics
News | December 30, 2025

Astal signs LoI with Immuna Therapeutics

Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation


Edgewise Therapeutics reports positive updates from HCM drug EDG-7500
Clinical Trials | December 30, 2025

Edgewise Therapeutics reports positive updates from HCM drug EDG-7500

CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM